A strong viral promoter has been developed for expression of therapeutic levels of various interfering RNA molecules. This composition of matter invention describes a viral cassette in a HSV-1 vector adjacent to a promoter that drives the expression of small interference RNAs (siRNA). The siRNA then suppress the activity of targeted genes through a trans acting mechanism. The major application is the suppression or silencing of the specifically targeted gene. Among the many uses of this would be the silencing or down regulation of various genes which may be over-expressed in various disease states or the activation of genes through silencing of its respective regulatory transactivator. This invention appears to be an improvement over commercially available products and has been shown to work in an animal model. There is a significant amount of activity in the development of therapeutic siRNAs; however, a long lead time is anticipated before the first commercial therapeutic is expected to enter the market. Use of this technology as a research tool could begin immediately. Envision the development of experimental kits for research purposes.
U.S. Patent Application #11/327,232
US 2006-0154370 A1 published 7/13/06
WO 2006/076251 published 7/20/06
Seeking licensing partner to develop and commercialize this technology
Licensing Status: Available for Exclusive License
Mr. Christopher Fasel
Associate Director or Licensing
UAMS BioVentures - TLO
Medical School - Teaching Hospital - Research InstitutionView profile
Clients in focus...